Biblioteca Virtual indica artigos

11 de novembro de 2016

Dia 12 de novembro acontece na sede da AMMG Reunião Multidisciplinar sobre o câncer de próstata. A Biblioteca Virtual da entidade selecionou os mais recentes artigos sobre o tema. Confira:

 

Tema: Rastreamento do câncer de próstata

Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis.

Cancer. 2016 Nov 15;122(21):3386-3393. doi: 10.1002/cncr.30192. Epub 2016 Jul 26.

PMID: 27459245

 

National Trends in Prostate Biopsy and Radical Prostatectomy Volumes Following the United States Preventative Services Task Force Guidelines Against Prostate-Specific Antigen Screening.

JAMA Surg. 2016 Nov 2. doi: 10.1001/jamasurg.2016.3987. [Epub ahead of print]

PMID: 27806151

 

Trends in Prostate Cancer Screening Following Changes Made by the US Preventive Services Task Force: Are We Turning Back the Clock?

JAMA Surg. 2016 Nov 2. doi: 10.1001/jamasurg.2016.3999. [Epub ahead of print]

PMID: 27806148

 

Assessing blood platelets as RNA biomarker source for prostate cancer.

Biomarkers. 2016 Nov;21(7):653-9. doi: 10.3109/1354750X.2016.1171909. Epub 2016 Apr 28.

PMID:  27121394

 

Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers.

Int J Mol Sci. 2016 Oct 26;17(11). pii: E1784.

PMID:  27792187

 

Informed decision making before prostate-specific antigen screening: Initial results using the American Cancer Society (ACS) Decision Aid (DA) among medically underserved men.

Cancer. 2016 Oct 11. doi: 10.1002/cncr.30367. [Epub ahead of print]

PMID:  27727462

 

Recent progress and perspectives on prostate cancer biomarkers.

Int J Clin Oncol. 2016 Oct 11. [Epub ahead of print]

PMID:  27730440

 

Prostate Specific Antigen-Growth Curve Model to Predict High-Risk Prostate Cancer.

Prostate. 2016 Oct 4. doi: 10.1002/pros.23258. [Epub ahead of print]

PMID: 27699819

 

The utility of urine-circulating miRNAs for detection of prostate cancer.

Br J Cancer. 2016 Sep 6;115(6):707-15. doi: 10.1038/bjc.2016.233. Epub 2016 Aug 4.

PMID: 27490805

 

What's new in screening in 2015?

Curr Opin Urol. 2016 Sep;26(5):447-58. doi: 10.1097/MOU.0000000000000321.

PMID: 27326657

 

Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer.

Curr Opin Urol. 2016 Sep;26(5):459-65. doi: 10.1097/MOU.0000000000000316.

PMID: 27262138

 

Computer-aided Detection of Prostate Cancer with MRI: Technology and Applications.

Acad Radiol. 2016 Aug;23(8):1024-46. doi: 10.1016/j.acra.2016.03.010. Epub 2016 Apr 25.

PMID: 27133005

 

Biomarker Discovery in Human Prostate Cancer: an Update in Metabolomics Studies.

Transl Oncol. 2016 Aug;9(4):357-70. doi: 10.1016/j.tranon.2016.05.004.

PMID: 27567960

 

 

Screening for familial and hereditary prostate cancer.

Int J Cancer. 2016 Jun 1;138(11):2579-91. doi: 10.1002/ijc.29949. Epub 2016 Feb 5.

PMID: 26638190

 

Prostate-specific antigen-based prostate cancer screening: Past and future.

Int J Urol. 2015 Jun;22(6):524-32. doi: 10.1111/iju.12750. Epub 2015 Apr 6.

PMID: 25847604

 

Impact of the U.S. Preventive Services Task Force recommendations against prostate specific antigen screening on prostate biopsy and cancer detection rates.

J Urol. 2015 May;193(5):1519-24. doi: 10.1016/j.juro.2014.11.096. Epub 2014 Dec 3.

PMID: 25481037

 

Prevention and early detection of prostate cancer.

Lancet Oncol. 2014 Oct;15(11):e484-92. doi: 10.1016/S1470-2045(14)70211-6.

PMID: 25281467

 

Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.

BJU Int. 2012 Dec;110(11 Pt B):E653-7. doi: 10.1111/j.1464-410X.2012.11398.x. Epub 2012 Aug 14.

PMID: 22892057

 

 

Tema: Vigilância Ativa no Câncer de Próstata

Prostate Cancer Prevention: Concepts and Clinical Trials.

Curr Urol Rep. 2016 Apr;17(4):35. doi: 10.1007/s11934-016-0587-1. Review.

PMID: 26957512

 

What should we tell prostate cancer patients about (secondary) prevention?

Curr Opin Urol. 2014 May;24(3):318-23. doi: 10.1097/MOU.0000000000000049. Review.

PMID: 24625429

 

Future directions in the prevention of prostate cancer.

Nat Rev Clin Oncol. 2014 Jan;11(1):49-60. doi: 10.1038/nrclinonc.2013.211. Review.

PMID: 24281061

 

Prostate cancer prevention: agent development strategies.

Recent Results Cancer Res. 2014;202:121-31. doi: 10.1007/978-3-642-45195-9_15.

PMID: 24531786

 

Prevention of prostate cancer: outcomes of clinical trials and future opportunities.

Am Soc Clin Oncol Educ Book. 2014:e76-80. doi: 10.14694/EdBook_AM.2014.34.e76. Review.

PMID: 24857150

 

Prostate cancer prevention: concepts and clinical recommendations.

Prostate Cancer Prostatic Dis. 2010 Dec;13(4):300-6. doi: 10.1038/pcan.2010.18. Review.

PMID: 20567257

 

Update on chemoprevention for prostate cancer.

Curr Opin Urol. 2010 May;20(3):194-7. doi: 10.1097/MOU.0b013e3283381966. Review.

PMID: 20216317

 

Chemoprevention of prostate cancer.

Urol Clin North Am. 2010 Feb;37(1):11-21, Table of Contents. doi: 10.1016/j.ucl.2009.11.003. Review.

PMID: 20152515

 

Tema : Recidivia Bioquímica de Câncer de Próstata

Intensity of stromal changes predicts biochemical recurrence-free survival in prostatic carcinoma.

Scand J Urol Nephrol. 2010 Nov;44(5):284-90. doi: 10.3109/00365599.2010.485578.

PMID: 20459359

 

Proposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy.

BJU Int. 2016 Aug;118(2):236-42. doi: 10.1111/bju.13229.

PMID: 26190356

 

Do Second Primary Cancers Affect the Risk of Biochemical Recurrence in Prostate CancerPatients Undergoing Radical Prostatectomy? A Propensity Score-Matched Analysis.

Clin Genitourin Cancer. 2016 Aug;14(4):e363-9. doi: 10.1016/j.clgc.2016.03.003.

PMID: 27105723

 

Magnetic resonance imaging for localization of prostate cancer in the setting of biochemicalrecurrence.

Urol Oncol. 2016 Jul;34(7):303-10. doi: 10.1016/j.urolonc.2016.01.004. Review.

PMID: 27012939

 

Preoperative Multiparametric Magnetic Resonance Imaging Predicts Biochemical Recurrence in Prostate Cancer after Radical Prostatectomy.

PLoS One. 2016 Jun 23;11(6):e0157313. doi: 10.1371/journal.pone.0157313.

PMID: 27336392

 

Biochemical recurrence-free survival and pathological outcomes after radical prostatectomy for high-risk prostate cancer.

BMC Urol. 2016 Jun 8;16(1):26. doi: 10.1186/s12894-016-0146-6.

PMID: 27267988

 

Prostate Cancer: Utility of Whole-Lesion Apparent Diffusion Coefficient Metrics for Prediction of Biochemical Recurrence After Radical Prostatectomy.

AJR Am J Roentgenol. 2015 Dec;205(6):1208-14. doi: 10.2214/AJR.15.14482.

PMID: 26587927

 

The natural course of pT2 prostate cancer with positive surgical margin: predicting biochemicalrecurrence.

World J Urol. 2015 Jul;33(7):973-9. doi: 10.1007/s00345-015-1510-y.

PMID: 25682109

 

Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.

Eur Urol. 2015 Jun;67(6):1160-7. doi: 10.1016/j.eururo.2014.09.019.

PMID: 25301759

 

Factors determining biochemical recurrence in low-risk prostate cancer patients who underwent radical prostatectomy.

Turk J Urol. 2015 Jun;41(2):61-6. doi: 10.5152/tud.2015.65624.

PMID: 26328203

 

Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence.

Eur Urol. 2015 Feb;67(2):204-9. doi: 10.1016/j.eururo.2014.09.017.

PMID: 25294696

 

Dual-phase 11C-choline PET/computed tomography in the early evaluation of prostate cancer recurrence.

Nucl Med Commun. 2015 Jan;36(1):8-15. doi: 10.1097/MNM.0000000000000207.

PMID: 25299466

 

Evaluation of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy.

J Nucl Med. 2015 May;56(5):668-74. doi: 10.2967/jnumed.115.154153.

PMID: 25791990

 

Patterns of Clinical Recurrence of Node-positive Prostate Cancer and Impact on Long-term Survival.

Eur Urol. 2015 Nov;68(5):777-84. doi: 10.1016/j.eururo.2015.04.035.

PMID: 25959166

 

SIGIRR/TIR8, an important regulator of TLR4 and IL-1R-mediated NF-κB activation, predicts biochemical recurrence after prostatectomy in low-grade prostate carcinomas.

Hum Pathol. 2015 Nov;46(11):1744-51. doi: 10.1016/j.humpath.2015.07.015.

PMID: 26344417

Management of patients with biochemical recurrence after local therapy for prostate cancer.

Hematol Oncol Clin North Am. 2013 Dec;27(6):1205-19, viii. doi: 10.1016/j.hoc.2013.08.005. Review.

PMID: 24188259

 

Association of microRNA-126 expression with clinicopathological features and the risk of biochemical recurrence in prostate cancer patients undergoing radical prostatectomy.

Diagn Pathol. 2013 Dec 18;8:208. doi: 10.1186/1746-1596-8-208.

PMID: 24350576

 

Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies.

Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):960-7. doi: 10.1016/j.ijrobp.2013.09.015.

PMID: 24351411

 

Survival following biochemical recurrence after radical prostatectomy and adjuvant radiotherapy in patients with prostate cancer: the impact of competing causes of mortality and patient stratification.

Eur Urol. 2013 Oct;64(4):557-64. doi: 10.1016/j.eururo.2013.03.006.

PMID: 23506833

 

Identification of miR-133b and RB1CC1 as independent predictors for biochemical recurrence and potential therapeutic targets for prostate cancer.

Clin Cancer Res. 2014 May 1;20(9):2312-25. doi: 10.1158/1078-0432.CCR-13-1588.

PMID: 24610824

 

Analysis of the expression of interleukins, interferon β, and nuclear factor-κ B in prostate cancer and their relationship with biochemical recurrence.

J Immunother. 2014 Sep;37(7):366-73. doi: 10.1097/CJI.0000000000000045.

PMID: 25075566

 

High miR-449b expression in prostate cancer is associated with biochemical recurrence after radical prostatectomy.

BMC Cancer. 2014 Nov 21;14:859. doi: 10.1186/1471-2407-14-859.

PMID: 25416653

 

Histologic confirmation of a biochemical recurrence after radical prostatectomy by performing 3-dimensional transrectal ultrasonography-guided biopsy with fusion to magnetic resonance imaging.

Urology. 2014 Nov;84(5):e17-8. doi: 10.1016/j.urology.2014.07.031.

PMID: 25443949

 

PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data.

Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):55-69. doi: 10.1007/s00259-015-3202-7. Review.

PMID: 26450693

 

Comparison of biochemical recurrence in prostate cancer patients treated with radical prostatectomy or radiotherapy.

Korean J Urol. 2015 Oct;56(10):703-9. doi: 10.4111/kju.2015.56.10.703.

PMID: 26495071

 

Tema : Novas perspectivas no tratamento do câncer de próstata avançado 

Statin derivatives as therapeutic agents for castration-resistant prostate cancer.

Cancer Lett. 2016 Dec 1;383(1):94-105. doi: 10.1016/j.canlet.2016.09.008.

PMID: 27687622

 

Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.

Oncotarget. 2016 Oct 10. doi: 10.18632/oncotarget.12554.

PMID: 27741508

 

Role of taxanes in advanced prostate cancer.

Clin Transl Oncol. 2016 Oct;18(10):972-80. doi: 10.1007/s12094-015-1480-y.

PMID: 26856599

 

Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer.

Oncologist. 2016 Sep 14. pii: theoncologist.2016-0161.

PMID: 27628492

 

The safety and efficacy of radium-223 dichloride for the treatment of advanced prostate cancer.

Expert Rev Anticancer Ther. 2016 Sep;16(9):911-8. doi: 10.1080/14737140.2016.1222273.

PMID: 27501059

 

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.

Eur Urol. 2016 Aug 31. pii: S0302-2838(16)30469-9. doi: 10.1016/j.eururo.2016.08.002. [Epub ahead of print]

PMID: 27591931

 

Galeterone for the treatment of advanced prostate cancer: the evidence to date.

Drug Des Devel Ther. 2016 Jul 15;10:2289-97. doi: 10.2147/DDDT.S93941. Review.

PMID: 27486306

 

Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer.

Curr Urol Rep. 2016 Apr;17(4):29. doi: 10.1007/s11934-016-0584-4.

PMID: 26902623

 

 

Acesse os artigos

*Exclusivo para sócios AMMG  e palestrantes do evento.